KING OF PRUSSIA, PA — Phio Pharmaceuticals Corp. (NASDAQ: PHIO) reported a widening third-quarter loss and a nearly 50% decline in cash reserves as the King of Prussia biotechnology company increased spending to prepare its experimental skin cancer treatment for a Phase 2b clinical trial in early 2027.
Phio reported a net loss of $4.2 million for the quarter ended September 30, 2026, compared with $2.4 million a year earlier. Cash and cash equivalents fell to $10.6 million from $21 million at the end of December 2025.
The increased spending reflects the company’s efforts to advance PH-762, an investigational treatment based on its proprietary INTASYL gene-silencing technology.
Research and development expenses rose 159% to $3 million during the quarter, compared with approximately $1.1 million a year earlier. The increase was primarily driven by toxicology studies, drug manufacturing and clinical supply preparations.
For the first nine months of 2026, research and development spending reached $8.9 million, up 180% from the comparable period in 2025. Management expects development expenses to continue increasing as the program advances.
General and administrative expenses declined 9% to $1.2 million during the third quarter, reflecting reduced spending on outside consulting services.
Phio also reported completing its first commercial-scale batch of PH-762’s active pharmaceutical ingredient under current Good Manufacturing Practice standards. The material has been shipped to a drug product manufacturer to support production of clinical trial supplies.
The manufacturing milestone follows completion of a Phase 1b clinical trial in June involving 22 patients with skin cancers, including 20 with cutaneous squamous cell carcinoma, one with melanoma and one with Merkel cell carcinoma.
The multicenter study evaluated the safety and tolerability of PH-762 administered directly into tumors before surgery, along with tumor response and appropriate dosing for further development.
Phio submitted its final Phase 1b clinical study report to the U.S. Food and Drug Administration, along with a meeting request and briefing materials outlining its proposed Phase 2b study in cutaneous squamous cell carcinoma.
The company expects FDA feedback by the end of November, a regulatory step that could influence the design and timing of the next clinical trial.
“We have successfully executed on critical development objectives to advance the PH-762 program toward Phase 2b study initiation,” said Robert J. Bitterman, Phio’s president and chief executive officer.
The company is targeting the first quarter of 2027 to begin the Phase 2b study, which would further evaluate PH-762 as a treatment administered before surgery.
Phio also reported holding 56 issued patents and 34 pending patent applications worldwide covering its RNA interference technology and product candidates. Existing intellectual property protections extend through at least 2038, with pending applications potentially extending coverage into 2044.
The company’s near-term priorities remain obtaining regulatory feedback, preparing clinical trial supplies and advancing PH-762 while managing the financial demands of a larger development program.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.
